Mustang Bio, Inc. Debt/Equity

Debt/Equity of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.


Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2021 was 0.02 (a -1.23% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Equity decreased by -46.67%
  • Annual Debt/Equity for 2020 was 0.02 (a -92.48% decrease from previous year)
  • Annual Debt/Equity for 2019 was 0.3 (a Infinity% increase from previous year)
  • Annual Debt/Equity for 2018 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Mustang Bio, Inc.

Most recent Debt/Equityof MBIO including historical data for past 10 years.

Interactive Chart of Debt/Equity of Mustang Bio, Inc.

Mustang Bio, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.02 0.02
2020 0.02 0.03 0.23 0.3 0.02
2019 0.26 0.22 0.18 0.45 0.3
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.88 0.0 0.0 0.01
2015 0.0 0.0

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.